Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY: GSK )

32.80 +0.72 (+2.24%)
Official Closing Price Updated: 6:30 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,782,285
Open 32.79
Bid (Size) 32.82 (6)
Ask (Size) 32.95 (1)
Prev. Close 32.08
Today's Range 32.51 - 32.92
52wk Range 31.71 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 4.71%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference
GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio. 
Via Benzinga
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily

Performance

YTD
-3.39%
-3.39%
1 Month
-2.32%
-2.32%
3 Month
-15.81%
-15.81%
6 Month
-15.68%
-15.68%
1 Year
-17.75%
-17.75%

More News

Read More
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion
Via Benzinga
GSK Enters Agreement to Acquire IDRx, Inc.
From GSK plc and IDRx, Inc.
Via Business Wire
Why CureVac (CVAC) Shares Are Volatile
Via Benzinga
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Via Benzinga
Topics ETFs
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
Via Benzinga
Exposures Product Safety
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
Via Benzinga
GSK's Sinus Disease Drug Secures Approval In China
Via Benzinga
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Via FinancialNewsMedia
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
From FN Media Group LLC
Via GlobeNewswire
Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
Via Benzinga
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, Kennedy
Via Investor's Business Daily
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
Via Investor's Business Daily
What's Going On Moderna Stock On Monday?
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children
Via Benzinga
Topics Government
Exposures Political Product Safety
Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination
Via Benzinga
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
Via Benzinga
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Via Benzinga
GSK's Blood Cancer Drug Shows Improved Survival Compared To Johnson & Johnson's Darzalex
Via Benzinga
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
From GSK plc
Via Business Wire
Oracle, Vertiv And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.